Lipella Pharmaceuticals Inc. (LIPO)
- Previous Close
0.7542 - Open
0.7500 - Bid --
- Ask --
- Day's Range
0.7400 - 0.7650 - 52 Week Range
0.6400 - 2.7100 - Volume
24,336 - Avg. Volume
62,586 - Market Cap (intraday)
5.811M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
www.lipella.comRecent News: LIPO
Performance Overview: LIPO
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIPO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIPO
Valuation Measures
Market Cap
5.16M
Enterprise Value
2.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.78
Price/Book (mrq)
1.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.27%
Return on Equity (ttm)
-118.13%
Revenue (ttm)
449.62k
Net Income Avi to Common (ttm)
-4.62M
Diluted EPS (ttm)
-0.7700
Balance Sheet and Cash Flow
Total Cash (mrq)
3.29M
Total Debt/Equity (mrq)
4.34%
Levered Free Cash Flow (ttm)
-1.52M
Research Analysis: LIPO
Company Insights: LIPO
LIPO does not have Company Insights